Ghanizadeh A, Moghimi-Sarani E
In some embodiments, the otoprotectant is a compound of Formula (XI) having the structure of Formula (XIa): In some embodiments, the otoprotectant is any one of the following compounds: or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate or hydrate, pharmaceutically acceptable salt hydrate, or pharmaceutically acceptable prodrug thereof
Clinically the disease is manifested after ~70% of dopaminergic neurones die
Plain language summary NAC may be an effective therapy for brain diseases because it reduces ROS and brain inflammation processes and regulates plasma glutamate
Developed through structure-based design from the ERR/-preferring scaffold GSK4716, SLU-PP-332 exhibits enhanced ERR activity by exploiting key - interactions within the receptor's ligand-binding domain (Billon et al
Supports antioxidant defence and protects cells from damage